This study evaluated the immunomodulatory effects of the second-generation, irreversible EGFR TKI afatinib in combination with the PD-1 antibody pembrolizumab and included acquisition of baseline and on-treatment biopsies and peripheral blood samples at serial time points to evaluate alterations in circulating immune cells and the tumor immune microenvironment. Here, PDCD1 is linked to neoplasm.